BPC157 & TB500
Body Protection Compound + Thymosin Beta-4A combined repair-peptide protocol for tissue, tendon, and joint recovery, dosed together and monitored with your consultant through the full course.
Two peptides, one protocol: BPC157 acts locally on tissue and tendon; TB500 supports cell migration and repair systemically. Evidence is preclinical and early-clinical, your consultant will be direct about what is and isn’t established. Full reference →
Who this is for
Adults recovering from soft-tissue injury, tendon strain, or repetitive training load, where a genuine recovery indication exists. Candidacy is decided with your consultant against your history and imaging, never by a checkout flow.
How the program works
Your consultant goes through your goals, history, and whether this therapy is appropriate. If it isn't, you'll hear that instead.
Baseline review of the injury, history, imaging if needed. Your pens ship cold-chain once your program is agreed.
Both peptides dose daily by micro-injection. A video review at week 4, with messaging in between.
Function and pain reviewed against baseline. Together you decide: continue, taper, or return to full load.
Common questions
Most protocols run 8-12 weeks. Some patients report earlier changes in pain and mobility, but tissue remodelling is slow biology. Your consultant reviews function at weeks 4 and 8 rather than promising a date.
They work on different parts of repair: BPC157 acts locally on tendon and gut-derived signalling, TB500 systemically on cell migration. Your consultant may suggest one alone; the pair is common, not automatic.
Your program is quoted in full after your consultation, before anything is supplied. There is no set program price because there is no off-the-shelf product: dose, duration and monitoring differ per patient and per injury.
The BPC-157 and TB-500 combination is a research peptide format that pairs BPC-157 (a 15-amino-acid Body Protection Compound derived from a gastric protein fragment) with TB-500 (a synthetic fragment of thymosin beta-4, a 43-amino-acid actin-sequestering peptide). The two compounds engage different mechanistic pathways and are studied together in tissue-repair research designs.
TB-500 is a commercial designation for a synthetic peptide derived from thymosin beta-4 (Tβ4), a naturally occurring 43-amino-acid actin-sequestering peptide. Commercial TB-500 is sometimes the full parent peptide and sometimes a synthetic fragment containing the active LKKTETQ motif. Always verify against the Certificate of Analysis which form is supplied.
BPC-157 is characterised mechanistically through the nitric oxide system and the FAK-paxillin pathway in tendon fibroblasts. TB-500 (thymosin beta-4) is characterised through actin sequestration and cell migration effects. They engage different molecular targets and converge on overlapping but distinct tissue-repair outcomes in published preclinical work.
The combination is studied in tissue-repair research designs across tendon, ligament, muscle, and gastric mucosal models. The pairing rationale is the complementarity of mechanisms (nitric oxide and FAK-paxillin from BPC-157; actin sequestration and progenitor mobilisation from TB-500). The combination has not been characterised in large peer-reviewed clinical trials; published evidence covers each peptide separately.
Two peptides, two mechanisms
BPC-157 effects on tissue repair are characterised mechanistically via the nitric oxide system (Klicek et al, J Pharmacol Sci, 2008) and FAK-paxillin phosphorylation in tendon fibroblasts (Chang et al, J Appl Physiol, 2011). The two pathways converge on cell migration and survival.
Thymosin beta-4 is the principal actin-sequestering peptide in eukaryotic cells. It binds G-actin monomers and modulates F-actin polymerisation dynamics. The actin-binding activity underlies the cell migration and tissue-repair effects observed across the published TB-4 literature.
Smart and colleagues (Nature, 2007;445(7124):177-182) reported that thymosin beta-4 induces adult epicardial progenitor mobilisation and neovascularisation. The progenitor-mobilisation property provides a candidate mechanism for tissue-repair effects across multiple organ systems.
The combination of BPC-157 and TB-500 in research protocols rests on the complementarity of distinct mechanistic pathways (nitric oxide and FAK-paxillin from BPC-157; actin sequestration and progenitor mobilisation from TB-500). Combination effects have not been characterised in large peer-reviewed clinical trials; the combination is studied in research community protocols.
BPC157 TB500 is also searched as Thymosin beta-4, Tβ4, BPC157 TB500.